Table 2.

Examples of NPs inducing potential complications and adverse events in some clinical trials.

Examples in clinical trials.gov (Identifier No.)	Administration routes	General disorders	Musculoskeletal and connective tissue disorders	Gastrointestinal disorders	Nervous system disorders	Blood and lymphatic disorders	Skin and subcutaneous tissue disorders	Construction strategies
NCT00629499	Intravenously	Fatigue	NA	Hemorrhage, vomiting	Mental Status	Hemoglobin, neutrophils	Rash, alopecia	Nab-paclitaxel-containing adjuvant NPs
NCT01620190	Interventional therapy	Fatigue	NA	NA	Peripheral Neuropathy	Hypotension, Neutrophil count decreased, White blood cells decreased	NA	Paclitaxel albumin-stabilized NPs
NCT02009332	Intravesical	Malaise	Worsening of edema of extremities	Nausea	Headache	Anemia,	Mucositis	A sterile lyophilized powder of albumin-bound sirolimus NPs
NCT00748553	Interventional therapy	Chills, Edema, Fever	Arthralgia, Muscle Weakness	Constipation,Diarrhea, Dry mouth, Hemorrhoids	Dizziness, Dysgeusia	Anemia, Thrombocy-topenia	Alopecia	Hypomethylating agent azacitidine (Vidaza) with the NPs albumin-bound paclitaxel (Abraxane)

All data in Table 2 were obtained from the database of the clinical trials.gov (https://clinicaltrials.gov/ct2/home) NA: not applicable